tiprankstipranks
Trending News
More News >
Quipt Home Medical (TSE:QIPT)
TSX:QIPT

Quipt Home Medical (QIPT) AI Stock Analysis

Compare
124 Followers

Top Page

TSE:QIPT

Quipt Home Medical

(TSX:QIPT)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
C$5.50
▲(13.40% Upside)
Quipt Home Medical's overall score is driven by strong technical momentum and strategic expansions, despite profitability challenges and valuation concerns. The company's ability to generate cash and strategic partnerships provide a positive outlook, but improvements in profitability are necessary for long-term growth.
Positive Factors
Strategic Partnerships
These partnerships expand Quipt's presence into Michigan and Ohio, enhancing market reach and providing a competitive edge in the healthcare sector.
Cash Flow Generation
Strong cash flow growth indicates effective cash generation, supporting operational needs and strategic investments, crucial for long-term sustainability.
Recurring Revenue
A high percentage of recurring revenue ensures a stable income stream, enhancing financial predictability and reducing reliance on new sales.
Negative Factors
Profitability Challenges
Negative profitability metrics indicate struggles in cost management and revenue efficiency, which could hinder long-term financial health.
Revenue Decline
Year-over-year revenue decline suggests potential market challenges or competitive pressures, impacting growth prospects if not addressed.
Increased Operating Expenses
Rising operating expenses can erode margins and profitability, necessitating improved cost control measures to sustain financial performance.

Quipt Home Medical (QIPT) vs. iShares MSCI Canada ETF (EWC)

Quipt Home Medical Business Overview & Revenue Model

Company DescriptionQuipt Home Medical Corp. provides in-home medical equipment and supplies, and respiratory and durable medical equipment in the United States. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company also provides bariatric equipment, bathroom safety products, bilevel positive airway pressure, canes/crutches, continuous positive airway pressure, CPAP masks and accessories, hospital beds, humidifiers, nebulizers and compressors, oxygen concentrators, patient lifts, walkers, wheelchairs, and products for wound care. In addition, it offers ventilators; home-based sleep apnea and chronic obstructive pulmonary disease treatments; home-based healthcare logistics and services; medical supplies, medical equipment, mobility equipment, and respiratory equipment; and CPAP and BiPAP units, ventilation equipment and aids, daily and ambulatory aides, and equipment solutions, as well as home and hospital delivery, and oxygen therapy services. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky.
How the Company Makes MoneyQuipt Home Medical generates revenue through multiple streams, primarily by providing durable medical equipment and related services to patients with chronic health conditions. The company earns money from the sale and rental of medical equipment, such as oxygen concentrators, CPAP machines, and mobility aids. Additionally, Quipt receives reimbursements from government programs like Medicare and Medicaid, as well as private insurance providers, for the medical equipment and services it supplies. Strategic partnerships with healthcare providers and institutions enhance its reach, while a focus on patient-centric services ensures a steady demand for its offerings.

Quipt Home Medical Earnings Call Summary

Earnings Call Date:Aug 11, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 16, 2026
Earnings Call Sentiment Neutral
Quipt Home Medical demonstrated important strategic expansions and maintained a steady adjusted EBITDA margin, indicating resilience and potential for future growth. However, there were declines in revenue year-over-year, a decrease in the customer base, and increased operating expenses, which highlight some ongoing challenges.
Q3-2025 Updates
Positive Updates
Revenue Stabilization and Organic Growth
Revenue for fiscal Q3 2025 was $58.3 million, a return to positive quarter-over-quarter organic growth of 1.6%, compared to $57.4 million in Q2 2025.
Strategic Health System Partnerships
Quipt announced partnerships with major health systems including Ballad Health and a joint venture with Henry Ford Health, McLaren Health, and Blanchard Valley Health, expanding presence into Michigan and Ohio.
Consistent Adjusted EBITDA Margin
Adjusted EBITDA margin remained steady at 23.5% in Q3 2025, showing consistent performance despite a dynamic environment.
Expansion and Infrastructure Growth
With over 160 locations across 27 states, Quipt serves over 325,000 active patients, supporting scalability and efficiency.
Strong Recurring Revenue
Recurring revenue for Q3 2025 was robust at 81% of total revenue, indicating a stable revenue stream.
Joint Venture with Hart Medical Equipment
The joint venture adds immediate scale with Hart generating approximately $60 million in revenue and $7 million in adjusted EBITDA.
Negative Updates
Decrease in Customer Base and Setups
The company's customer base decreased, serving 151,000 unique patients as of June 30, 2025 compared to 153,000 in 2024, and setups/deliveries decreased from 216,000 in Q3 2024 to 210,000 in Q3 2025.
Revenue Decline Year-Over-Year
Revenue for fiscal Q3 2025 decreased by 4.1% to $58.3 million from $60.8 million in Q3 2024.
Increased Operating Expenses
Operating expenses as a percentage of revenue rose to 53.3% in Q3 2025 from 50.4% in the corresponding period in 2024.
Net Loss Increase
Net loss for Q3 2025 was $3 million or $0.07 per diluted share, compared to $1.6 million loss or $0.04 per diluted share in Q3 2024.
Decrease in Cash on Hand
The company reported $11.3 million of cash on hand as of June 30, 2025, down from $17.1 million as of March 31, 2025.
Company Guidance
During the third quarter of fiscal year 2025, Quipt Home Medical Corp. reported a return to positive organic growth and revenue stabilization. The company achieved $58.3 million in revenue, reflecting a 1.6% quarter-over-quarter increase, though it was a 4.1% decrease from the previous year's quarter. Adjusted EBITDA margin was consistent at 23.5%, with adjusted EBITDA totaling $13.7 million. Despite a net loss of $3 million or $0.07 per diluted share, cash flow from operations improved to $27.9 million for the nine months ended June 30, 2025. The company completed 210,000 unique setups/deliveries and maintained strong recurring revenue at 81% of total revenue. Quipt also announced a strategic joint venture with Hart Medical Equipment, enhancing their Midwest presence and projecting an annualized run rate revenue of roughly $300 million. This joint venture is expected to provide an immediate scale, with Hart generating approximately $60 million in revenue and $7 million in adjusted EBITDA as of June 30, 2025. The company's focus remains on operational excellence, with strategic expansions and partnerships set to drive long-term growth and shareholder value.

Quipt Home Medical Financial Statement Overview

Summary
Quipt Home Medical shows strong revenue growth, but faces profitability challenges with negative net income and EBIT margins. The balance sheet is stable but increasing leverage could pose risks. Cash flow is strong, indicating good cash generation, but profitability improvements are needed.
Income Statement
65
Positive
Quipt Home Medical has demonstrated strong revenue growth, with a 49.38% increase in the latest year, indicating a robust expansion trajectory. However, the company is facing profitability challenges, as evidenced by negative net income and EBIT margins. The gross profit margin remains healthy, suggesting efficient cost management at the production level, but the negative net profit margin highlights issues in controlling operating expenses or other costs.
Balance Sheet
58
Neutral
The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the return on equity is negative, reflecting the company's struggle to generate profit from shareholders' equity. The equity ratio is stable, suggesting a solid asset base relative to equity, but the increase in total debt over the years could pose a risk if not managed carefully.
Cash Flow
72
Positive
Cash flow analysis reveals a strong growth in free cash flow, up by 71.48%, which is a positive indicator of the company's ability to generate cash. The operating cash flow to net income ratio is favorable, suggesting efficient cash generation relative to reported earnings. However, the reliance on free cash flow to cover net income indicates that profitability improvements are necessary for long-term sustainability.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue271.13M343.09M245.91M211.68M139.86M102.35M
Gross Profit177.18M177.18M176.99M153.78M106.65M74.18M
EBITDA51.30M48.32M51.07M45.14M28.05M10.45M
Net Income-10.70M-10.70M-6.76M-2.78M4.84M-6.17M
Balance Sheet
Total Assets425.45M425.45M247.25M247.41M132.21M108.57M
Cash, Cash Equivalents and Short-Term Investments17.97M17.97M16.17M17.21M8.52M34.61M
Total Debt118.79M118.79M99.80M97.96M26.56M27.05M
Total Liabilities269.48M269.48M140.06M136.29M52.67M49.95M
Stockholders Equity139.69M139.69M107.19M111.11M79.55M58.62M
Cash Flow
Free Cash Flow28.47M35.43M25.07M33.75M17.38M13.65M
Operating Cash Flow41.53M52.71M35.38M40.54M26.34M18.69M
Investing Cash Flow-42.22M-46.07M-10.31M-82.83M-42.49M-17.84M
Financing Cash Flow-1.64M-10.85M-26.15M50.87M-9.85M3.91M

Quipt Home Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.85
Price Trends
50DMA
3.52
Positive
100DMA
3.47
Positive
200DMA
3.16
Positive
Market Momentum
MACD
0.37
Negative
RSI
85.24
Negative
STOCH
98.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:QIPT, the sentiment is Positive. The current price of 4.85 is above the 20-day moving average (MA) of 3.75, above the 50-day MA of 3.52, and above the 200-day MA of 3.16, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 85.24 is Negative, neither overbought nor oversold. The STOCH value of 98.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:QIPT.

Quipt Home Medical Risk Analysis

Quipt Home Medical disclosed 47 risk factors in its most recent earnings report. Quipt Home Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Quipt Home Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
C$213.53M-14.05-10.51%2.48%-53.76%
54
Neutral
C$315.82M-5.60-127.60%72.03%-1.47%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
C$39.84M-8.86-269.41%1.46%6.91%
46
Neutral
C$37.22M-1.67-181.70%209.29%35.38%
44
Neutral
C$23.48M-5.6528.59%23.46%
40
Underperform
C$67.80M-11.07-188.03%-52.41%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:QIPT
Quipt Home Medical
4.85
1.40
40.58%
TSE:PINK
Perimeter Medical Imaging AI
0.35
-0.05
-12.50%
TSE:PRN
Profound Medical
10.46
0.46
4.60%
TSE:TLT
Theralase Technologies
0.16
-0.08
-33.33%
TSE:VPT
VentriPoint Diagnostics
0.14
0.04
40.00%
TSE:BLO
Cannabix Technologies
0.56
0.24
72.31%

Quipt Home Medical Corporate Events

Quipt Home Medical’s Strategic Moves Amid Financial Challenges
Sep 1, 2025

Quipt Home Medical Corp’s recent earnings call painted a picture of strategic resilience amidst some financial challenges. The company showcased important strategic expansions and maintained a steady adjusted EBITDA margin, signaling potential for future growth. However, the call also highlighted declines in revenue year-over-year, a decrease in the customer base, and increased operating expenses, pointing to ongoing challenges that the company must address.

M&A TransactionsRegulatory Filings and Compliance
Quipt Home Medical Rejects Forager’s Acquisition Proposal
Negative
Aug 27, 2025

On August 27, 2025, Quipt Home Medical Corp. confirmed receipt of another unsolicited, non-binding proposal from Forager Capital Management, LLC to acquire all of the company’s shares at $3.10 per share, a reduction from a previous offer of $3.90 per share in January 2025. The board of Quipt Home Medical has rejected these offers, citing undervaluation and concerns over Forager’s failure to comply with U.S. securities laws. The board remains focused on enhancing long-term shareholder value and is open to engaging with Forager if they agree to a confidentiality agreement.

The most recent analyst rating on (TSE:QIPT) stock is a Hold with a C$3.50 price target. To see the full list of analyst forecasts on Quipt Home Medical stock, see the TSE:QIPT Stock Forecast page.

Quipt Home Medical Corp Faces Shareholder Activism Challenges: Implications for Operations and Market Stability
Aug 13, 2025

Quipt Home Medical Corp faces significant risks from proxy contests and actions by activist shareholders, which can disrupt operations and divert management’s focus. Despite agreements like the Kanen and Forager Agreements to mitigate these risks, the potential for costly and time-consuming disputes remains. Such uncertainties can deter business opportunities and complicate the retention of key personnel, potentially impacting the company’s strategic plans and financial stability. Additionally, these activities may lead to share price volatility, further affecting investor confidence and the company’s market position.

Business Operations and StrategyM&A Transactions
Quipt Home Medical Expands Midwest Presence Through Strategic Joint Venture
Positive
Aug 12, 2025

Quipt Home Medical has announced a strategic joint venture with three major health systems, acquiring a 60% stake in Hart Medical Equipment. This move is set to enhance Quipt’s presence in the Midwest, particularly with its entry into the Michigan market, and is expected to add $60 million in revenue. The partnership will strengthen Quipt’s integration with healthcare systems, leveraging Hart’s established relationships with hospitals and care facilities. The transaction is anticipated to close by the end of Fiscal Q4, 2025, and is expected to align with Quipt’s strategic goals of expanding its service network and improving patient care outcomes.

The most recent analyst rating on (TSE:QIPT) stock is a Buy with a C$8.50 price target. To see the full list of analyst forecasts on Quipt Home Medical stock, see the TSE:QIPT Stock Forecast page.

Business Operations and StrategyFinancial DisclosuresM&A Transactions
Quipt Home Medical Achieves Positive Growth and Expands Reach with Strategic Acquisition
Positive
Aug 11, 2025

Quipt Home Medical reported its fiscal third quarter 2025 results, highlighting a return to positive organic growth with a 1.6% increase in quarter-over-quarter revenue, despite a year-over-year decrease. The company achieved an adjusted EBITDA of 23.5% of revenue and maintained strong recurring revenue at 81%. Operationally, Quipt expanded its reach through the acquisition of a durable medical equipment provider, enhancing its presence in the Appalachian Highlands region and securing a Preferred Provider Agreement with Ballad Health. This strategic move is expected to align the acquired operation’s margins with Quipt’s historical range, supporting long-term growth and stability.

The most recent analyst rating on (TSE:QIPT) stock is a Buy with a C$8.50 price target. To see the full list of analyst forecasts on Quipt Home Medical stock, see the TSE:QIPT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 19, 2025